Stockscreener 앱 받기
38.94
0.79%
-0.31
전일 마감가:
$39.25
열려 있는:
$39.57
하루 거래량:
2.31M
Relative Volume:
0.72
시가총액:
$5.98B
수익:
-
순이익/손실:
$-284.08M
주가수익비율:
-16.07
EPS:
-2.4234
순현금흐름:
$-234.65M
1주 성능:
+10.16%
1개월 성능:
-2.63%
6개월 성능:
+228.33%
1년 성능:
+378.97%
1일 변동 폭
$38.59
$41.35
1주일 범위
$33.84
$41.35
52주 변동 폭
$3.72
$43.73
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
COGT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
38.94 | 6.03B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-10 | 업그레이드 | Stifel | Hold → Buy |
| 2025-11-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-10-16 | 개시 | Stifel | Hold |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
Geopolitics Watch: What are Cogent Biosciences Incs recent SEC filings showingShort Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
(COGT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - Sahm
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next - TechStock²
Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1%Still a Buy? - MarketBeat
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio - Investing News Network
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - MSN
Cogent Biosciences Announces Anticipated 2026 Commercial - GlobeNewswire
Cogent Biosciences, Inc. Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio - marketscreener.com
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) - Finviz
Cogent Biosciences announces proposed concurrent public offerings - MSN
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Cogent Biosciences Inc. stock a buy for dividend growthDurability and Wear Notes & lightweight options for faster days - ulpravda.ru
Cogent Biosciences, Inc. (COGT) Stock Analysis: Unlocking A 41% Upside Potential - DirectorsTalk Interviews
Cogent Bio surges after late-stage trial data for lead drug - MSN
A Look At Cogent Biosciences (COGT) Valuation After Positive Bezuclastinib NDA Filing - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Stock Rating Upgraded by UBS Group - MarketBeat
Aug Ideas: Is Cogent Biosciences Inc. stock a buy for dividend growth2025 Macro Impact & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Will Cogent Biosciences Inc. stock split again soon2025 Volume Leaders & Reliable Price Breakout Signals - ulpravda.ru
Will Cogent Biosciences Inc. stock deliver long term returnsWeekly Profit Summary & Community Consensus Trade Signals - ulpravda.ru
Why Cogent Biosciences Inc. stock is in analyst buy zone2025 EndofYear Setup & Free Technical Confirmation Trade Alerts - ulpravda.ru
Will Cogent Biosciences Inc. stock outperform growth indexesQuarterly Growth Report & Precise Entry and Exit Recommendations - Улправда
How Cogent Biosciences Inc. stock performs during Fed tightening cyclesMarket Movers & Safe Entry Point Identification - ulpravda.ru
Will Cogent Biosciences Inc. stock attract more institutional investorsJuly 2025 Sentiment & Verified Entry Point Detection - ulpravda.ru
Does Cogent Biosciences Inc. stock trade at a discount to peersJuly 2025 Market Mood & Smart Swing Trading Alerts - ulpravda.ru
Cogent Biosciences price target raised to $52 from $50 at HC Wainwright - MSN
Does Cogent Biosciences (COGT) Bezuclastinib NDA Redefine Its Competitive Position in Mastocytosis Treatment? - Sahm
Cogent Biosciences announces presentation at the 44th annual J.P. Morgan Healthcare conference - marketscreener.com
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cogent Biosciences, Inc. CEO Andrew Robbins to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COG - GuruFocus
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COGT Stock News - GuruFocus
Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily
Cogent Biosciences down after market close on insider sales - MSN
Best Biotech Stocks To Follow TodayDecember 31st - MarketBeat
Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding - simplywall.st
EV Market: Will Cogent Biosciences Inc stock see PE expansionJuly 2025 News Drivers & Capital Efficiency Focused Ideas - moha.gov.vn
Cogent Biosciences Stock Jumps in 2025 as Executives Sell Shares - Barron's
Cogent Biosciences, Inc. (COGT) Stock Analysis: Potential 38% Upside as Analysts Show Strong Buy Interest - DirectorsTalk Interviews
When Will Cogent Biosciences, Inc. (NASDAQ:COGT) Become Profitable? - 富途牛牛
Voya Investment Management LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing - ts2.tech
Cogent Biosciences (NASDAQ:COGT) Shares Gap Down Following Insider Selling - MarketBeat
Cogent Biosciences Stock Pre-Market (-4.4%): Insider Selling Overwhelms Positive NDA News - Trefis
Wave of High-Level Insider Sales Rocks Cogent Biosciences - TipRanks
Cogent Biosciences presents full SUMMIT results of bezuclastinib - MSN
Insider Sell: Jessica Sachs Sells 82,642 Shares of Cogent Biosci - GuruFocus
Cogent Biosciences (COGT) Shares Drop Following Insider Sales - GuruFocus
Cogent Biosciences stock falls after multiple insider sales By Investing.com - Investing.com UK
Cogent Biosciences stock falls after multiple insider sales - Investing.com
Cogent Biosciences (NASDAQ:COGT) Insider Sells $3,198,245.40 in Stock - MarketBeat
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
코젠트 바이오사이언시스 주식 (COGT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Green John L. | Chief Financial Officer |
Dec 26 '25 |
Sale |
38.68 |
77,000 |
2,978,360 |
131,834 |
| Sachs Jessica | Chief Medical Officer |
Dec 26 '25 |
Sale |
38.70 |
82,642 |
3,198,245 |
133,938 |
| Robinson John Edward | Chief Scientific Officer |
Dec 26 '25 |
Sale |
38.74 |
90,000 |
3,486,600 |
140,002 |
4.73%
0.92%
자본화:
|
볼륨(24시간):